The fact that the DN PDGFRA totally impeded mECK36 tumorigenesis validates PDGFRA as an oncogenic driver and it shows that approaches that fully and stably inhibit PDGFR-signaling could be successful therapeutic strategies in KS. This evidence concerns the gene PDGFRB and Kaposi's sarcoma.